Bevacizumab Against Recurrent Retinal Detachment (BEARRD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02192970|
Recruitment Status : Active, not recruiting
First Posted : July 17, 2014
Last Update Posted : March 5, 2019
|Condition or disease||Intervention/treatment||Phase|
|Retinal Detachment Proliferative Vitreoretinopathy||Drug: Bevacizumab||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||102 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Actual Study Start Date :||January 21, 2015|
|Estimated Primary Completion Date :||October 2019|
|Estimated Study Completion Date :||April 2020|
Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
Other Name: Avastin
No Intervention: Chart review
Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.
- Complete success of primary vitrectomy surgery [ Time Frame: 6 months ]Complete success of primary vitrectomy surgery, defined as retinal re-attachment without the need for any additional surgical procedures.
- Presence of proliferative vitreoretinopathy [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02192970
|United States, Wisconsin|
|University of Wisconsin|
|Madison, Wisconsin, United States, 53705|
|Principal Investigator:||Michael Altaweel, MD||University of Wisconsin, Madison|